Background: Hemorrhagic shock and trauma are associated with acidosis and altered
coagulation. A fall in pH has been reported to attenuate the activity of recombinant activated …

Background: The interplay of coagulopathy, acidosis, and hypothermia contributes to the
death of the most seriously injured trauma patients. Because of in vitro testing and …

Background: Previous experiments with diverse pig models to evaluate the ability of rFVIIa to
reduce hemorrhage have provided divergent results. The current study was conducted to …

As interest in the use of activated recombinant factor VII (rFVIIa) in trauma grows, questions
arise regarding how best to monitor rFVIIa therapy and when rFVIIa may be expected to …

Background: Activated factor VII catalyzes the activation of clotting factors IX and X within the
clotting cascade, and has been used clinically to decrease bleeding in patients with …

Background: Recombinant activated factor VII (rFVIIa) is currently administered off-label to
control diffuse coagulopathic bleeding of patients with traumatic injuries. These patients are …

Background Intravenous administration of recombinant activated human clotting factor VII
(rFVIIa) has been used successfully to prevent bleeding in hemophilia patients undergoing …

Background Recombinant activated factor VII (rFVIIa) was approved for treatment of
hemorrhages in patients with hemophilia who develop inhibitors to factors VIII or IX …

Background Recombinant factor VIIa (rFVIIa) is registered for use in haemophilia with
inhibitors and other rare bleeding disorders, but has also been used in various other clinical …

Abstract Background Recombinant factor VIIa (rFVIIa) has been successfully used in various
clinical conditions to treat severe coagulopathy, but its efficacy may be affected by the …